3-methyl-4,5,6,7-tetrahydro-isoxazolo[4,5-c]pyridine | 84574-26-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-methyl-4,5,6,7-tetrahydro-isoxazolo[4,5-c]pyridine
• 英文别名: 3-methyl-4,5,6,7-tetrahydro-[1,2]oxazolo[4,5-c]pyridine
• CAS: 84574-26-5
• 化学式: C₇H₁₀N₂O
• mdl: MFCD18072028
• 分子量: 138.169
• InChiKey: DMBBYTNJMFNFAT-UHFFFAOYSA-N

物化性质

• 沸点：
  271.0±35.0 °C(Predicted)
• 密度：
  1.109±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  38.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-methyl-4,5,6,7-tetrahydro-isoxazolo[4,5-c]pyridine 、 苯甲酰氯 生成 (3-Methyl-6,7-dihydro-4H-isoxazolo[4,5-c]pyridin-5-yl)-phenyl-methanone
  参考文献：
  名称：

  ADEMBRI, G.;CAMPARINI, A.;PONTICELLI, F.;TEDESCHI, P., TETRAHEDRON LETT., 1982, 23, N 42, 4375-4378

  摘要：

  DOI：
• 作为产物：
  描述：

  3-methyl-isoxazolo(4,5-c)pyridine 、 borane tetrahydrofuran 以30%的产率得到
  参考文献：
  名称：

  ADEMBRI, G.;CAMPARINI, A.;PONTICELLI, F.;TEDESCHI, P., TETRAHEDRON LETT., 1982, 23, N 42, 4375-4378

  摘要：

  DOI：

文献信息

• [EN] OCTAHYDROCYCLOPENTAPYRROLES, THEIR PREPARATION AND USE<br/>[FR] OCTAHYDROCYCLOPENTAPYRROLES, LEUR PRÉPARATION ET LEUR UTILISATION
  申请人：UNIV COLUMBIA

  公开号：WO2014152018A1

  公开（公告）日：2014-09-25

  The present invention provides Octahydrocyclopentapyrrole compounds having the structure: (structurally represented) wherein psi is absent or present, and when present is a bond; R1, R2, R3, R4, and R5 are each independently H, halogen, CF, or C1-C4 alkyl; R6 is absent or present, and when present is H, OH, or halogen; A is absent or present, and when present is C(O) or C(O)NH; B is substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, benzyl, CO2H or (C1-C4 alkyl)-CO2H, wherein when B is CO2H, then A is present and is C(O); and when psi is present, then R6 is absent and when psi is absent, then R6 is present, or a pharmaceutically acceptable salt thereof, for treatement of diseases characterized by excessive lipofuscin accumulation in the retina.

  本发明提供了具有以下结构的八氢环戊吡咯化合物：(结构表示) 其中psi为不存在或存在，当存在时为键；R1、R2、R3、R4和R5各自独立为H、卤素、CF或C1-C4烷基；R6不存在或存在，当存在时为H、OH或卤素；A不存在或存在，当存在时为C(O)或C(O)NH；B为取代或未取代的单环、双环、杂单环、杂双环、苄基、CO2H或(C1-C4烷基)-CO2H，其中当B为CO2H时，A存在且为C(O)；且当psi存在时，R6不存在，当psi不存在时，R6存在，或其药用可接受盐，用于治疗以视网膜过度脂褐素积聚为特征的疾病。
• [EN] PROTEOLYSIS TARGETING CHIMERIC (PROTAC) COMPOUND WITH E3 UBIQUITIN LIGASE BINDING ACTIVITY AND TARGETING ALPHA-SYNUCLEIN PROTEIN FOR TREATING NEURODEGENERATIVE DISEASES<br/>[FR] COMPOSÉ CHIMÈRE CIBLANT LA PROTÉOLYSE (PROTAC) AYANT UNE ACTIVITÉ DE LIAISON À L'UBIQUITINE LIGASE E3 ET CIBLANT UNE PROTÉINE ALPHA-SYNUCLÉINE POUR LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
  申请人：ARVINAS OPERATIONS INC

  公开号：WO2020041331A1

  公开（公告）日：2020-02-27

  The present disclosure relates to bifunctional compounds, which find utility as modulators of alpha-synuclein (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/ inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure. Such diseases or disorders are alpha-synucleinopathies or neurodegenerative diseases associated with alpha-synuclein accumulation and aggregation, such as e.g. Parkinson Disease, Alzheimer's Disease, dementia, dementia with Lewy bodies or multiple system atrophy, in particular Parkinson's Disease.

  本公开涉及双功能化合物，其作为α-突触核蛋白（目标蛋白）的调节剂具有实用性。具体而言，本公开涉及包含一端为Von Hippel-Lindau、cereblon、凋亡抑制蛋白或鼠双分子同源物2配体的双功能化合物，该配体与相应的E3泛素连接酶结合，另一端为与目标蛋白结合的基团，使得目标蛋白靠近泛素连接酶以促使目标蛋白的降解（和抑制）。本公开展示了与目标蛋白的降解/抑制相关的广泛药理活性范围。本公开的化合物和组合物用于治疗或预防由目标蛋白聚集或积累导致的疾病或紊乱。这些疾病或紊乱是与α-突触核蛋白积累和聚集相关的α-突触核蛋白病或神经退行性疾病，例如帕金森病、阿尔茨海默病、痴呆症、带有Lewy小体的痴呆症或多系统萎缩，特别是帕金森病。
• Triazine Derivatives
  申请人：Pfizer Inc.

  公开号：US20140329820A1

  公开（公告）日：2014-11-06

  The present invention is directed to a new class of triazine derivatives as described by formula I below in which A, X, R 1 , R 2 , R 3 , and R 4 are as defined herein and to the use of the compounds as PDE10 inhibitors.

  本发明涉及一种新的三嗪衍生物类别，如下式所示，其中A、X、R1、R2、R3和R4如本文所定义，并且涉及将这些化合物用作PDE10抑制剂。
• SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS
  申请人：HAURAND Michael

  公开号：US20090075978A1

  公开（公告）日：2009-03-19

  The present invention relates to substituted propiolic acid amides, to methods for the production thereof, to medicaments containing these compounds and to the use thereof for producing medicaments.

  本发明涉及取代丙炔酸酰胺，以及其生产方法、含有这些化合物的药物和用于生产药物的用途。
• [EN] N-ALKYL-2-PHENOXYETHANAMINES, THEIR PREPARATION AND USE<br/>[FR] N-ALKYL-2-PHÉNOXYÉTHANAMINES, LEURS PRÉPARATION ET UTILISATION
  申请人：UNIV COLUMBIA

  公开号：WO2014151959A1

  公开（公告）日：2014-09-25

  The present invention provides a compound having the structure: (structurally represented) wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl; R6 is alkyl; A is absent or present, and when present is -C(O)- or -C(O)NH-; B is substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, benzyl, CO2H or (C1-C4 alkyl)-CO2H, wherein when B is CO2H, then A is present and is -C(O)-, or a pharmaceutically acceptable salt thereof.

  本发明提供一种具有以下结构的化合物：（结构表示）其中R1、R2、R3、R4和R5分别独立地为H、卤素、CF3或C1-C4烷基；R6为烷基；A为不存在或存在，当存在时为-C(O)-或-C(O)NH-；B为取代或未取代的单环、双环、杂单环、杂双环、苄基、CO2H或（C1-C4烷基）-CO2H，其中当B为CO2H时，A存在且为-C(O)-，或其药用盐。